Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
This study has been terminated.
( See Detailed Description )
Study NCT00031278   Information provided by Pfizer
First Received: February 28, 2002   Last Updated: December 15, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma, Metastatic Breast
Additional conditions recognized in this trial
Breast Neoplasms
Carcinoma
Neoplasm Metastasis
More general conditions related to this trial
Breast Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplastic Processes
Pathologic Processes
Skin Diseases
Interventions listed in this trial
CPG 7909
Herceptin®
Additional drug interventions recognized in this trial
Trastuzumab
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services